

Press release

Epigenomics AG: Noel Doheny Appointed as New CEO of US-Subsidiary Epigenomics Inc.

Berlin, Germany, and Seattle, WA, USA, April 20, 2011 - Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnosis company, today announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary Epigenomics Inc. in Seattle, WA, USA, reporting to Geert Nygaard, CEO of Epigenomics AG. Mr. Doheny will start in his new position in early May 2011.

Mr. Doheny has 30+ years of experience in the field of diagnostics, with over 20 years in senior management. In his most recent position as CEO of OpGen (2008-2009), Mr. Doheny led the transformation of an incubator lab services company into a systems company in less than two years. Prior to this, he held positions as Senior Vice President for the Molecular Diagnostics Division of Affymetrix Inc., Vice President of Pre-Analytical Solutions and a member of the Executive Committee at QIAGEN as well as President and CEO of BioStar Inc. (known as ThermoBioStar post-acquisition). Importantly for Epigenomics as it continues to build a US sales force, he has built several operating teams from the ground up, including the commercial teams to launch novel products at companies such as Ciba Corning, ThermoBiostar, and OpGen. Mr. Doheny obtained degrees in Biology and Chemistry from West Virginia University and attended Georgetown University for post-graduate studies in Biochemistry prior to moving into industry.

"With the Company gearing up for the pre-market approval submission of Epi *pro*Colon[®] 2.0 to the FDA, I am absolutely delighted to be given this opportunity to build the commercial strategy and the team for a successful launch of the test in the USA and very much look forward to joining Epigenomics' management team," commented Noel Doheny on his appointment as CEO of Epigenomics Inc..

Geert Nygaard, Chief Executive Officer of Epigenomics said: "I would like to welcome Noel as the new CEO of our U.S.-based subsidiary, Epigenomics Inc., who comes with a very strong commercial background with broad scientific and medical expertise. Noel's extensive experience in the diagnostics industry, along with his marketing and sales know-how, will be instrumental in helping us strengthen our commercial operations in the US and driving the transformation of that organization into a commercial molecular diagnostics enterprise. We are pleased to welcome him to the team and believe that his experience will be crucial at this pivotal stage of the company."

-Ends-

| |
|-------------------------------|
| Contact Epigenomics AG |
|-------------------------------|

| |
|---|
| Dr. Achim Plum Sen. VP Corporate Development Epigenomics AG Tel +49 (0) 30 24345 368 pr@epigenomics.com www.epigenomics.com |
|---|

epigenomics

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company's products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company's technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.

***Epigenomics legal disclaimer.** This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*